Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes
Inflammatory breast cancer (IBC) is highly metastatic at the onset of the disease with no IBC-specific treatments, resulting in dismal patient survival. IBC treatment is a clear unmet clinical need. This commentary highlights findings from a recent seminal approach in which pembrolizumab, a checkpoi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/18/2850 |
| _version_ | 1827662480468344832 |
|---|---|
| author | Daniel Alonso-Miguel Steven Fiering Hugo Arias-Pulido |
| author_facet | Daniel Alonso-Miguel Steven Fiering Hugo Arias-Pulido |
| author_sort | Daniel Alonso-Miguel |
| collection | DOAJ |
| description | Inflammatory breast cancer (IBC) is highly metastatic at the onset of the disease with no IBC-specific treatments, resulting in dismal patient survival. IBC treatment is a clear unmet clinical need. This commentary highlights findings from a recent seminal approach in which pembrolizumab, a checkpoint inhibitor against programmed cell death protein 1 (PD-1), was provided to a triple-negative IBC patient as a neoadjuvant immune therapy combined with anthracycline–taxane-based chemotherapy. We highlight the findings of the case report and offer a perspective on taking a proactive approach to deploy approved immune checkpoint inhibitors. On the basis of our recently published research study, we propose in situ vaccination with direct injection of immunostimulatory agents into the tumor as an option to improve outcomes safely, effectively, and economically for IBC patients. |
| first_indexed | 2024-03-10T00:26:37Z |
| format | Article |
| id | doaj.art-5e11a24d3e2949a688225c56a4181d89 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T00:26:37Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-5e11a24d3e2949a688225c56a4181d892023-11-23T15:33:17ZengMDPI AGCells2073-44092022-09-011118285010.3390/cells11182850Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient OutcomesDaniel Alonso-Miguel0Steven Fiering1Hugo Arias-Pulido2Department of Animal Medicine and Surgery, Veterinary Medicine School, Complutense University of Madrid, 28040 Madrid, SpainDepartment of Microbiology and Immunology, and Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Health, Lebanon, NH 03756, USADepartment of Microbiology and Immunology, and Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Health, Lebanon, NH 03756, USAInflammatory breast cancer (IBC) is highly metastatic at the onset of the disease with no IBC-specific treatments, resulting in dismal patient survival. IBC treatment is a clear unmet clinical need. This commentary highlights findings from a recent seminal approach in which pembrolizumab, a checkpoint inhibitor against programmed cell death protein 1 (PD-1), was provided to a triple-negative IBC patient as a neoadjuvant immune therapy combined with anthracycline–taxane-based chemotherapy. We highlight the findings of the case report and offer a perspective on taking a proactive approach to deploy approved immune checkpoint inhibitors. On the basis of our recently published research study, we propose in situ vaccination with direct injection of immunostimulatory agents into the tumor as an option to improve outcomes safely, effectively, and economically for IBC patients.https://www.mdpi.com/2073-4409/11/18/2850inflammatory breast cancerneoadjuvant immunotherapytriple-negative breast cancerimmune checkpoint inhibitorspembrolizumabimmunomodulators |
| spellingShingle | Daniel Alonso-Miguel Steven Fiering Hugo Arias-Pulido Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes Cells inflammatory breast cancer neoadjuvant immunotherapy triple-negative breast cancer immune checkpoint inhibitors pembrolizumab immunomodulators |
| title | Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes |
| title_full | Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes |
| title_fullStr | Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes |
| title_full_unstemmed | Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes |
| title_short | Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes |
| title_sort | proactive immunotherapeutic approaches against inflammatory breast cancer may improve patient outcomes |
| topic | inflammatory breast cancer neoadjuvant immunotherapy triple-negative breast cancer immune checkpoint inhibitors pembrolizumab immunomodulators |
| url | https://www.mdpi.com/2073-4409/11/18/2850 |
| work_keys_str_mv | AT danielalonsomiguel proactiveimmunotherapeuticapproachesagainstinflammatorybreastcancermayimprovepatientoutcomes AT stevenfiering proactiveimmunotherapeuticapproachesagainstinflammatorybreastcancermayimprovepatientoutcomes AT hugoariaspulido proactiveimmunotherapeuticapproachesagainstinflammatorybreastcancermayimprovepatientoutcomes |